Novocure Launches Campaign to Drive Awareness and Understanding of Tumor Treating Fields Therapy
Novocure (NASDAQ: NVCR) has launched a campaign to increase awareness of Tumor Treating Fields (TTFields) therapy, emphasizing its potential as a distinct anticancer treatment for solid tumors. This innovative therapy utilizes electric fields to selectively kill cancer cells, aiming to address poor survival rates in many cancers. The campaign includes a new website and is designed to educate healthcare providers and patients about the multimechanistic action of TTFields. Novocure intends to equip the oncology community with knowledge to enhance patient outcomes globally.
- Launch of an educational campaign to raise awareness about Tumor Treating Fields therapy.
- TTFields therapy offers a distinct mechanism to target and kill cancer cells without significantly affecting healthy cells.
- Potential for enhanced clinical application across various solid tumor types, as shown in preclinical studies.
- None.
Campaign urges healthcare providers to harness the versatile power of electric fields to outsmart solid tumors
ROOT,
With a poor survival outlook across many solid tumors, physicians and patients need additional treatment strategies that utilize innovative modalities. Novocure’s educational campaign includes a new website and aims to build awareness around key elements of TTFields therapy, including its versatile modality, its multimechanistic action and its potential for versatile clinical application across solid tumors as shown in preclinical studies. The TTFields therapy campaign uses the iconography of the Queen, the most powerful and versatile piece of the chess board, to highlight the clinical versatility of this innovative anticancer modality.
“We’re excited to launch this campaign to drive awareness and help the oncology community understand the science of Tumor Treating Fields,” said Novocure’s Chief Commercial Officer
To learn more about Tumor Treating Fields therapy and its multifaceted effect on cancer cells, visit tumortreatingfieldstherapy.com.
About Tumor Treating Fields
TTFields are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. TTFields do not significantly affect healthy cells because they have different properties (including division rate, morphology, and electrical properties) than cancer cells. The multiple, distinct mechanisms of TTFields therapy work together to selectively target and kill cancer cells. Due to its multimechanistic actions, TTFields therapy can be added to cancer treatment modalities in approved indications and demonstrates enhanced effects across solid tumor types when used with chemotherapy, radiotherapy, immune checkpoint inhibition, or PARP inhibition in preclinical models. TTFields therapy provides clinical versatility that has the potential to help address treatment challenges across a range of solid tumors. To learn more about Tumor Treating Fields therapy and its multifaceted effect on cancer cells, visit tumortreatingfieldstherapy.com.
About Novocure
Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure’s commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma and malignant pleural mesothelioma. Novocure has ongoing or completed clinical studies investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer. Headquartered in Root,
Forward-Looking Statements
In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, clinical study progress, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, coverage, collections from third-party payers and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, environmental, regulatory and political conditions as well as issues arising from the COVID-19 pandemic and other more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on
View source version on businesswire.com: https://www.businesswire.com/news/home/20221020005708/en/
Investors:
investorinfo@novocure.com
610-723-7427
Media:
media@novocure.com
610-723-7428
Source: Novocure
FAQ
What is the purpose of Novocure's new campaign related to NVCR?
What are Tumor Treating Fields in relation to NVCR?
How does TTFields therapy work according to Novocure's press release?
What types of cancer can benefit from TTFields therapy as mentioned in the NVCR press release?
